Allergy Diagnostics And Therapeutics Market (2025 - 2033)

Allergy Diagnostics And Therapeutics Market Summary

The global allergy diagnostics and therapeutics market size was estimated at USD 34.42 billion in 2024 and is projected to reach USD 78.00 billion by 2033, growing at a CAGR of 9.7% from 2025 to 2033. Some of the major factors driving the market are rising incidence of allergies, advancements in technology and launch of new products, and high adoption of immunotherapy drugs.

In November 2022, the Global Allergy and Airways Patient Platform reported that approximately 30-40% of people today have one or more allergies, and the number of people with allergies has been increasing over the past 20 years. Furthermore, changing lifestyle and growing pollution are some of the key factors contributing to the increasing incidence of allergic conditions. The introduction of therapeutically advanced drugs namely immunotherapy, which solves unmet patient needs, is expected to boost market growth over the forecast period. For instance, in February 2024, the U.S. Food and Drug Administration approved Xolair (omalizumab) injection for immunoglobulin E-mediated food allergy in certain adults and children 1 year or older for the reduction of allergic reactions (Type I), including reducing the risk of anaphylaxis, that may occur with accidental exposure due to more than one food. Also, Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.

The rising prevalence of allergies is one of the important reasons driving the growth of the allergy therapeutics market over the predicted period. High risk factors for chronic respiratory disorders include increased exposure to outdoor and indoor air pollution, as well as occupational exposure. Allergies are far more common in cities than in rural areas, owing to increased exposure to environmental contaminants due to industrial activity and urbanization.

According to statistics published by WHO in January 2024, around 1 in 4 children and 1 in 3 adults have a seasonal allergy in the U.S. Nearly 6% of children and adults in the U.S. suffer from a food allergy, with the rate being highest among black, Asian, and Hispanic individuals. Similarly, as per data from the Asthma and Allergy Foundation of America, in 2021, in the U.S., about 81 million people were diagnosed with seasonal allergic rhinitis, representing around 26% affected adults and 19% affected children.

Increasing demand for IVD testing is likely to drive the allergy diagnostics and therapeutics market over the forecast period. In vitro blood tests are used to diagnose food, inhalation, skin, and medication allergies. These tests have several advantages, including the fact that they are minimally invasive, cost-effective, and user-friendly, which is expected to provide profitable growth prospects in this market. Furthermore, the development of low-cost and effective in vitro diagnostic tests for allergy detection, increased lab automation, and an increase in reagent rental agreements are all projected to contribute to market expansion in the future years.

Market Concentration & Characteristics

The allergy diagnostics and therapeutics market demonstrates high innovation, driven by AI/digital health in diagnosis, molecular diagnostics, and multiplex assays. Metropolis Healthcare Limited (India) launched a novel testing platform based on Component Resolved Diagnostics (CRD) to support India’s population diagnose various forms of allergies. This platform is a fourth-generation allergy testing technology that uses artificial intelligence (AI) in order to assist clinicians in making sound clinical decisions as well as provide great insights into selecting and optimizing the course of treatment regarding an individual’s allergic disease.

The market has medium mergers and acquisitions (M&A) that are increasingly shaping the allergy diagnostics and therapeutics market by consolidating major players, driving innovation, and expanding capabilities. Moreover, M&A enables companies to leverage synergies, accelerate product development pipelines, and integrate complementary technologies.

The allergy diagnostics and therapeutics market has a significant regulatory influence because it regulates product efficacy, manufacturing quality, and patient safety. Further, regulatory agencies such as the European Medicine Agency, the FDA, the Japan Pharmaceutical and Medical Devices Authority, and other global healthcare authorities enforce stringent standards for both therapeutics and diagnostics.

Product expansion in the global allergy diagnostics and therapeutics market is medium, reflecting steady growth. In diagnostics, product expansion is driven by the development of multiplex testing systems, molecular-based assays, and point-of-care devices. On the therapeutics side, the market is seeing gradual growth in immunotherapy, target desensitization protocols, and biologic treatment for severe allergies. However, innovation is largely centered on improving existing therapies rather than launching new molecules.

North America plays a leading role in the allergy diagnostics and therapeutics market owing to the strong regulatory frameworks, well-established healthcare infrastructure, and high prevalence of allergic conditions. Further, the region benefits from many clinical trials, significant investment in R&D, and widespread adoption of innovative technologies.

Type Insights

The diagnostic segment is anticipated to experience the fastest CAGR during the forecast period in the allergy diagnostics and therapeutics market due to increasing demand for precise and early identification of allergic conditions. Diagnostics are pivotal in evaluating allergen sensitivities, enabling targeted therapeutic interventions. Consumables accounted for the largest revenue share in 2024 and is anticipated to grow at a significant CAGR due to its indispensable applications in diagnostic tests. Associated benefits such as availability of kits specific to each allergen and ease of access are expected to fuel this segment’s growth during the forecasted period.For instance, Allergen microarray kits, which have become more sensitive and provide individualized patient assessment & monitoring, are expected to propel the industry even further.

The therapeutics accounted for the largest revenue share of 83.46% in 2024 due to its focus on treating allergic conditions. Therapeutics aim to alleviate symptoms and provide relief from allergies, addressing the core concern of patients. Epinephrine dominated the overall allergy therapeutics market due to its rapid and potent response. Its swift action during severe allergic reactions, such as anaphylaxis. As a natural hormone, it mimics body's fight-or-flight response, swiftly alleviating symptoms such as respiratory distress and low blood pressure. Its ubiquity, cost-effectiveness, and decades-long established use contribute to its dominance, making it a crucial and trusted tool in emergency allergy management.

Allergen Type Insights

Inhaled allergies held the largest revenue share of 49.77% in 2024 owing to the growing incidence of respiratory allergies caused by industrialization and increasing air pollution. In August 2025, London Allergy Care and Knowledge, hospital reported that asthma affected approximately 20% of schoolchildren in the UK, allergic rhinitis and conjunctivitis (hay fever) affects about 15% of children, eczema (atopic dermatitis) affects 10-16% of children, and food allergies affect 6-8% of children.

Drug allergies are expected to experience the fastest CAGR over the forecast period. Drug allergies may lead to toxic epidermal necrolysis and Steven-Johnson syndrome in children. Chemotherapy drugs, sulfonamide drugs, and antiepileptic drugs are the most common agents of drug allergies. These allergens lead to various diseases such as contact dermatitis, which is skin inflammation. The segment is expected to showcase positive growth during the coming years due to increasing availability of treatment options and growing awareness about drug allergies among patients.

Test Type Insights

In vitro test accounted for a share of 51.54% of allergy diagnostics and therapeutics market in 2024. This test is utilized to identify allergen-specific immunoglobulin E. (IgE). Serum IgE has a higher positive predictive value and better specificity for detecting aeroallergen (pollen & insect) sensitization. These factors are expected to have a significant impact on allergy diagnostics market penetration during the forecast period. Furthermore, food allergy is a growing public health concern, with rising rates in both developed & developing nations. For example, according to Food Allergy Research and Education's 2022 statistics, approximately 2.8 million Americans are anticipated to have egg allergy in 2020 and 2.5 million will have wheat allergy.

In vivo test is estimated to grow at a significant CAGR over the forecast period, attributed to increasing adoption of several in vivo tests due to its convenient, cost-effective, safe & reliable properties as compared to others. Growing demand for rapid, simple, and efficient testing, has fueled the growth of in vivo diagnostic tests. These tests look at the susceptibility and reactivity of dermal mast cells, which can indicate allergic sensitivity. To ensure reliability, these procedures include skin exams with standardized allergenic extracts.

Regional Insights

North America allergy diagnostics and therapeutics market is the leading region with a revenue share of 36.53% in 2024 owing to factors such as rising incidence of allergy and favorable government initiatives in the region. North America is a developed region with high healthcare expenditure. The region held a major market share due to an increase in understanding of the high potential associated with allergy drugs.

U.S. Allergy Diagnostics and Therapeutics Market Trends

The allergy diagnostics and therapeutics market in the U.S. is driven by rising allergy prevalence, greater healthcare spending, and a strong emphasis on early and precise diagnosis. The presence of advanced healthcare infrastructure, significant R&D investments, and a high clinical awareness all contribute to rapid market expansion. For instance, in October 2024, FDA approved AccuTest allergy skin testing device. This test provides smaller tine lengths and diameters, which improve precision and lessen discomfort as well AccuTest trays feature non-slip rubber bottoms for better stability. Favorable payment schemes and the rapid adoption of new technology, such as molecular diagnostics and biologic drugs, drive demand even higher. Furthermore, FDA regulations help enable faster product approvals and market entry. The rising emphasis on tailored treatment and preventive care creates new opportunities for targeted allergy therapies. These factors make the U.S. a global leader in developing and applying allergy tests and therapies.

Europe Allergy Diagnostics and Therapeutics Market Trends

The European allergy diagnostics and therapeutics market is expected to grow rapidly, driven by an increase in the prevalence of allergic disorders, increased public health awareness, and the implementation of demanding regulatory criteria such as the EU In Vitro Diagnostic Regulation (IVDR). The region has advantages from a well-established healthcare system, many global and regional market competitors, and increasing investments in new diagnostic technology. European governments promote preventive healthcare, increasing demand for early allergy identification and individualized treatments. Furthermore, increased access to biologic therapies and sublingual immunotherapy (SLIT) is driving therapeutic market expansion. With continuous research projects and cross-border cooperation, Europe remains a significant allergy care innovation and growth region.

The UK allergy diagnostics and therapies market is growing steadily due to the rising prevalence of allergic disorders such as asthma, hay fever, and food allergies. A strong emphasis on public health efforts and government-funded healthcare via the NHS promotes broad access to diagnostic and treatment services. The market benefits from improving clinical awareness, improved diagnostic tools, and the increased availability of targeted therapeutics such as sublingual immunotherapy and biologics. Regulatory conformity with EU and MHRA standards assures product quality and safety, while ongoing investment in research and innovation drives market growth. For instance, in August 2025, a study funded by King’s College London and Guy’s and St Thomas’ NHS Foundation Trust to research on for the cheaper and more accurate test to diagnose milk allergy in children. Moreover, the basophil activation test (BAT) is more accurate than standard allergy tests for detecting cow’s milk allergy in children that can reduce the need for oral food challenges in allergy diagnosis. Furthermore, rising demand for tailored treatment and preventive allergy care contribute to the sector's continued growth.

The market for allergy treatments and diagnostics in Germany is expanding steadily due to the increased incidence of allergic diseases, particularly food and respiratory allergies. Early identification and efficient treatment of allergy problems are promoted by the nation's comprehensive healthcare system and a strong emphasis on preventative care. Germany leads the world in medical research and development, encouraging the use of cutting-edge immunotherapies such as biologics and sublingual medicines as well as modern diagnostic equipment. Improved market access is a result of stringent regulatory compliance within national and EU frameworks as well as supportive reimbursement policies. Additionally, increased partnerships among pharmaceutical corporations, biotech companies, and academic institutions are accelerating the research and commercialization of new products. These characteristics make Germany a major force in the European allergy care market.

Asia Pacific Allergy Diagnostics and Therapeutics Market Trends

Asia Pacific allergy diagnostics and therapeutics market is expected to grow at a lucrative rate owing to various factors, such as increasing healthcare reforms and expanding healthcare infrastructure. Other factors contributing to the market growth are growing population, rising incidence of allergies, and increasing number of local companies entering the market. Asia Pacific, with Japan, China, and India being notable markets in this region, is projected to boost the market within the region. Key players in these countries are undertaking various strategic initiatives to increase their dominance in the market. For instance, in October 2022, Siemens Healthineers divided Asia Pacific into two regions (China and the rest of Asia Pacific) to achieve its full potential in the region.

Japan Allergy Diagnostics and Therapeutics Market Trends

Japan's allergy diagnostics and therapies market is steadily rising, owing to the increased prevalence of allergic disorders, particularly among urban populations. Japan's aging population, combined with increased prevalence of respiratory and food allergies, is driving the demand for precise diagnostic tools and effective treatment options. The country has an advanced healthcare system and significant government assistance for early disease detection and prevention. The expanding use of molecular diagnostics drives increased market potential, the expansion of biologic medicines, and a well-defined regulatory framework. Furthermore, collaborations between domestic and foreign healthcare companies are pushing innovation and product availability, establishing Japan as a key market in Asia-Pacific for allergy management.

China Allergy Diagnostics and Therapeutics Market Trends

The China allergy diagnostics and therapeutics market is witnessing strong growth, supported by increase in allergy incidence caused by urbanization, environmental pollution, and changing lifestyles in China is driving the demand for allergy tests and treatments. The need for precise diagnosis and cutting-edge therapies is being pushed by rising middle-class demand for improved healthcare and increased public awareness of allergy-related conditions. Government attempts to improve healthcare infrastructure and increase access to specialist treatment are accelerating the industry's growth. Furthermore, point-of-care testing, allergen-specific immunotherapies, and molecular diagnostics are becoming increasingly popular in China, sometimes thanks to collaborations with foreign companies. Regulatory improvements aimed at accelerating pharmaceutical and device approvals also encourage international investment and innovation in the allergy sector.

Latin America Allergy Diagnostics and Therapeutics Market Trends

Growing knowledge of allergic diseases, improved healthcare facilities, and improvements in public health infrastructure are all contributing to the slow but steady growth of the Latin American market for allergy diagnostics and therapeutics. Country such as Brazil, Mexico, and Argentina are at the forefront of the region's adoption of modern diagnostic tools and the expansion of immunotherapy and other allergy treatments. In addition, market development is being aided by government attempts to enhance primary care services and encourage early diagnosis. Restricted reimbursement processes, financial constraints, and unequal access to specialized care in rural and urban areas continue to be major problems. A greater focus on managing chronic illnesses and growing partnerships with global healthcare organizations will enable additional market expansion in the years to come, despite these obstacles.

Middle East and Africa Allergy Diagnostics and Therapeutics Market Trends

The Middle East and Africa allergy diagnostics and therapies market is continuously growing, owing to the rising prevalence of allergic illnesses, urbanization, and greater exposure to environmental allergens. Increasing awareness of allergy-related health risks, advancement in the healthcare infrastructure, and government investments in public health encourage diagnostic tests and innovative therapeutics products. Moreover, key markets, such as South Africa, Saudi Arabia, and the UAE, are driving regional development by expanding access to specialist and private healthcare services. Also, while obstacles such as limited healthcare access in rural areas and regulatory inconsistencies exist, increased cooperation with multinational healthcare companies and efforts to improve early disease detection are expected to maintain market momentum.

Key Allergy Diagnostics and Therapeutics Company Insights

The allergy diagnostics & therapeutics industry is highly competitive and market players are involved in activities such as strategic collaborations, new product launches, acquisitions, technological advancements, and regional expansion.

Recent Developments

• In August 2025, Sanofi launched Allegra-D, a non-drowsy allergy relief from nasal decongestion in India. Allegra-D tablets include a fixed-dose combination (FDC) of Fexofe nadine Hydrochloride IP (60 mg), a non-drowsy antihistamine, and Pseudoephedrine Hydrochloride IP (120 mg), a powerful nasal decongestant. The formulation has got approval from the Drug Controller General of India (DCGI) for usage in adults and children aged 12 and older.

• In October 2024, Astria Therapeutics, Inc announced a license agreement with Inchon’s Sciences. The agreement covers the OX40 portfolio, particularly focusing on development of STAR-0310 for potential treatment of atopic dermatitis (AD) and other allergic and immunological diseases.

• In January 2024, ALK received FDA approval for expanded use of ODACTRA, a sublingual immunotherapy tablet in the treatment of house dust mite-induced allergic rhinitis for adolescents aged 12 through 17.

Allergy Diagnostics and Therapeutic Market